Publications by authors named "D Z Besson"
Article Synopsis
- * The study introduces enhanced modeling techniques for neutrino flux and detector response, and it distinguishes between starting (inside) and throughgoing (outside) neutrino interaction events to improve energy resolution.
- * The findings indicate a best-fit point for the 3+1 model with sin²(2θ_{24})=0.16 and Δm_{41}²=3.5 eV², supporting previous studies while showing consistency with no evidence of sterile neutrinos, as reflected
The coronavirus pandemic outbreak of 2019 highlighted the critical importance of preparedness for current and future public health threats (https://www.mmv.org/mmv-open/global-health-priority-box/about-global-health-priority-box).
View Article and Find Full Text PDFArticle Synopsis
- The CABASTY study investigated the effects of biweekly administration of a lower dose of cabazitaxel on pain and quality of life for older men with metastatic castration-resistant prostate cancer (mCRPC).
- In a trial involving 196 patients, researchers compared biweekly dosing (16 mg/m) to a standard triweekly dosing (25 mg/m) regarding pain progression and health-related quality of life (HRQoL).
- Results showed no significant differences in pain progression or HRQoL between treatment groups, but the biweekly group experienced a delayed onset of some adverse events, suggesting it could be a safer option for older patients.
Background: This randomized controlled trial examined the feasibility of adding eccentric exercise to a conventional cardiac rehabilitation program (CCRP) for coronary heart disease patients.
Methods: Ninety-three patients were randomly assigned to either the MIX group (eccentric ergometer + CCRP) or the CON group (concentric ergometer + CCRP) for 7 weeks. Training effectiveness was assessed based on "good responders" showing improved functional capacities, such as 6-minute walk test (6MWT) distance and maximal voluntary contraction of the plantar flexors (ankle MVC).
Despite the efforts towards malaria eradication, latest estimates show that the number of malaria cases is still rising, and malaria continues to have a devastating impact on people's health and livelihoods particularly in populations located in sub-Saharan Africa . As a Product Development Partnership (PDP), MMV Medicines for Malaria Venture (MMV) plays a crucial role by using public and philanthropic funds to engage the pharmaceutical industry and academic research institutions to discover, develop and deliver the new drugs needed to control and eradicate malaria. MMV Discovery, working with partners, has developed a robust pipeline of molecules and a reliable discovery engine able to support research projects from screening to candidate nomination, providing access to centers of expertise and evaluating the profile and potential of molecules.
View Article and Find Full Text PDF